loading
前日終値:
$0.5387
開ける:
$0.5438
24時間の取引高:
484.37K
Relative Volume:
0.24
時価総額:
$137.84M
収益:
$175.04M
当期純損益:
$-44.52M
株価収益率:
-1.1343
EPS:
-0.5338
ネットキャッシュフロー:
$-56.05M
1週間 パフォーマンス:
+7.10%
1か月 パフォーマンス:
-15.93%
6か月 パフォーマンス:
-42.10%
1年 パフォーマンス:
-18.50%
1日の値動き範囲:
Value
$0.5438
$0.608
1週間の範囲:
Value
$0.5316
$0.6079
52週間の値動き範囲:
Value
$0.5316
$2.05

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile

Name
名前
Adaptimmune Therapeutics Plc Adr
Name
セクター
Healthcare (1188)
Name
電話
44 1235 430000
Name
住所
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Name
職員
449
Name
Twitter
@Adaptimmune
Name
次回の収益日
2024-12-13
Name
最新のSEC提出書
Name
ADAP's Discussions on Twitter

ADAP を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ADAP
Adaptimmune Therapeutics Plc Adr
0.6065 137.84M 175.04M -44.52M -56.05M -0.18
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
408.13 103.71B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
717.41 78.28B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
626.32 36.77B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.22 30.35B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
115.31 27.32B 3.30B -501.07M 1.03B -2.1146

Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-07-30 開始されました H.C. Wainwright Buy
2024-05-30 開始されました Scotiabank Sector Outperform
2023-03-24 開始されました Bryan Garnier Buy
2023-01-03 アップグレード Guggenheim Neutral → Buy
2022-11-09 アップグレード Mizuho Neutral → Buy
2021-05-28 開始されました Barclays Underweight
2020-04-22 開始されました Mizuho Neutral
2019-08-02 ダウングレード Guggenheim Buy → Neutral
2019-05-31 開始されました ROTH Capital Buy
2019-05-30 再開されました Citigroup Buy
2019-05-07 ダウングレード SVB Leerink Outperform → Mkt Perform
2017-03-17 開始されました Wells Fargo Market Perform
2016-10-24 ダウングレード BofA/Merrill Neutral → Underperform
2016-09-30 開始されました Raymond James Outperform
2016-02-25 開始されました Citigroup Buy
2015-06-01 開始されました BofA/Merrill Neutral
2015-06-01 開始されました Guggenheim Buy
2015-06-01 開始されました Leerink Partners Outperform
すべてを表示

Adaptimmune Therapeutics Plc Adr (ADAP) 最新ニュース

pulisher
Dec 23, 2024

AST SpaceMobile Inc Still Hasn’t Convinced Analysts? - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

These Numbers Show Just How Powerful Standard Lithium Ltd (AMEX: SLI) Stock ‎Is - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

What Did We Note About Insider Trading At Lithium Americas Corp (NewCo) (NYSE: LAC)? - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Workhorse Group Inc (NASDAQ: WKHS) Could Pass $3.5 In One Year Stock Forecast - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Barnes & Noble Education Inc (NYSE: BNED) -10.53% Decline Turns Investors Away - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Applied Digital Corporation (NASDAQ: APLD) Could Pass $10 In One Year Stock Forecast - Stocks Register

Dec 23, 2024
pulisher
Dec 23, 2024

Asana Inc (NYSE: ASAN) Up 15.57% This Year: What Is Going To Happen Next - Stocks Register

Dec 23, 2024
pulisher
Dec 16, 2024

Adaptimmune's SWOT analysis: TCR-T pioneer faces challenges in stock outlook - Investing.com

Dec 16, 2024
pulisher
Dec 04, 2024

Adaptimmune's SWOT analysis: TCR-T therapy pioneer faces challenges post-FDA nod - Investing.com

Dec 04, 2024
pulisher
Dec 02, 2024

Royal Dutch Shell Plc ADR (SHEL-N) QuotePress Release - The Globe and Mail

Dec 02, 2024
pulisher
Nov 27, 2024

Mizuho lowers Adaptimmune price target by 50%, citing pipeline shifts and cost cuts - Investing.com

Nov 27, 2024
pulisher
Nov 18, 2024

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT)’s Stock Reduces -12.58%, Making It A Good Investment - Stocks Register

Nov 18, 2024
pulisher
Nov 18, 2024

Analysts Predict Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) To Loss -577.97% From Current Levels. - Stocks Register

Nov 18, 2024
pulisher
Nov 14, 2024

Earnings call: Adaptimmune outlines new strategy amid Tecelra launch By Investing.com - Investing.com South Africa

Nov 14, 2024
pulisher
Nov 14, 2024

Adaptimmune stock holds Buy rating with lower target amid Q3 revenue outperformance - Investing.com

Nov 14, 2024
pulisher
Nov 05, 2024

ADAPAdaptimmune Therapeutics plc American Depositary Shares Latest Stock News & Market Updates - StockTitan

Nov 05, 2024
pulisher
Nov 01, 2024

Adaptimmune faces Nasdaq delisting over share price - Investing.com India

Nov 01, 2024
pulisher
Oct 17, 2024

NVIDIA Corp (NVDA): Be Patient, You Will Learn - Stocks Register

Oct 17, 2024
pulisher
Oct 16, 2024

Investing in HUYA Inc ADR (HUYA): What You Must Know - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Checking in on Blackstone Inc (BX) after recent insiders movement - Knox Daily

Oct 16, 2024
pulisher
Oct 16, 2024

Ready to Jump After Recent Trade: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Oct 16, 2024
pulisher
Oct 14, 2024

Ratio Examination: Adaptimmune Therapeutics Plc ADR (ADAP)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 14, 2024
pulisher
Oct 14, 2024

Was anything negative for Adaptimmune Therapeutics Plc ADR (ADAP) stock last session? - US Post News

Oct 14, 2024
pulisher
Oct 10, 2024

Chief Commercial Officer Piccina Cintia sale 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP] - Knox Daily

Oct 10, 2024
pulisher
Oct 09, 2024

The Significance of Moving Averages in Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance - The InvestChronicle

Oct 09, 2024
pulisher
Oct 08, 2024

Technical analysis of Adaptimmune Therapeutics Plc ADR (ADAP) stock chart patterns - US Post News

Oct 08, 2024
pulisher
Oct 07, 2024

Adaptimmune Therapeutics Plc ADR (ADAP)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex

Oct 07, 2024
pulisher
Oct 04, 2024

A significant driver of top-line growth: Adaptimmune Therapeutics Plc ADR (ADAP) - SETE News

Oct 04, 2024
pulisher
Oct 02, 2024

Analysts review Adaptimmune Therapeutics Plc ADR’s rating - Knox Daily

Oct 02, 2024
pulisher
Oct 02, 2024

How should investors view Adaptimmune Therapeutics Plc ADR (ADAP)? - US Post News

Oct 02, 2024
pulisher
Oct 02, 2024

Recent Insider Activity Could Benefit Zentalis Pharmaceuticals Inc (ZNTL) - Knox Daily

Oct 02, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Adaptimmune stock faces challenges despite FDA win - Investing.com

Sep 27, 2024
pulisher
Sep 25, 2024

Stocks of Adaptimmune Therapeutics Plc ADR (ADAP) are poised to climb above their peers - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

Insider Sale Alert: Gap, Inc. [GAP] – Is it Time to sell? - Knox Daily

Sep 25, 2024
pulisher
Sep 25, 2024

Adaptimmune Therapeutics Plc ADR [ADAP] Piccina Cintia sells 24,531 Shares for $22814.0 - Knox Daily

Sep 25, 2024
pulisher
Sep 24, 2024

Adaptimmune finalizes settlement with Genentech - Investing.com India

Sep 24, 2024
pulisher
Sep 23, 2024

ADAP’s price-to-sales ratio: Is it a good investment opportunity? - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Ratios Uncovered: Breaking Down Adaptimmune Therapeutics Plc ADR (ADAP)’s Trailing Twelve Months Metrics - The Dwinnex

Sep 23, 2024
pulisher
Sep 20, 2024

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing - Yahoo Finance UK

Sep 20, 2024
pulisher
Sep 20, 2024

Adaptimmune Therapeutics Plc ADR Inc. (ADAP) Price Performance: Is It Undervalued or Overvalued? - The InvestChronicle

Sep 20, 2024
pulisher
Sep 18, 2024

Recent Insider Activity Could Benefit Adaptimmune Therapeutics Plc ADR (ADAP) - Knox Daily

Sep 18, 2024
pulisher
Sep 18, 2024

Zumiez Inc’s latest rating changes from various analysts - Knox Daily

Sep 18, 2024
pulisher
Sep 17, 2024

AdaptHealth Stock Earns RS Rating Upgrade - MSN

Sep 17, 2024
pulisher
Sep 17, 2024

A new trading data show Adaptimmune Therapeutics Plc ADR (ADAP) is showing positive returns. - SETE News

Sep 17, 2024
pulisher
Sep 16, 2024

Predicting Adaptimmune Therapeutics Plc ADR’s (ADAP) earnings for the current quarter - US Post News

Sep 16, 2024
pulisher
Sep 13, 2024

Director SIMON WILLIAM E JR acquire 45,000 shares of Douglas Emmett Inc [DEI] - Knox Daily

Sep 13, 2024
pulisher
Sep 13, 2024

Buying Buzz: Noble Corp Plc [NE] 10% Owner APMH Invest A/S purchases 324,984 shares of the company - Knox Daily

Sep 13, 2024
pulisher
Sep 10, 2024

There is no doubt that Adaptimmune Therapeutics Plc ADR (ADAP) ticks all the boxes. - SETE News

Sep 10, 2024
pulisher
Sep 09, 2024

Analyzing Ratios: Adaptimmune Therapeutics Plc ADR (ADAP)’s Financial Story Unveiled - The Dwinnex

Sep 09, 2024
pulisher
Sep 09, 2024

Adaptimmune Therapeutics Plc ADR (ADAP) stock analysis: A simple moving average approach - US Post News

Sep 09, 2024
pulisher
Sep 06, 2024

A company insider recently sold 24,531 shares of Adaptimmune Therapeutics Plc ADR [ADAP]. Should You Sale? - Knox Daily

Sep 06, 2024

Adaptimmune Therapeutics Plc Adr (ADAP) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Adaptimmune Therapeutics Plc Adr (ADAP) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Rawcliffe Adrian
Chief Executive Officer
Jan 17 '24
Sale
0.67
30,080
20,244
44,848
Rawcliffe Adrian
Chief Executive Officer
Jan 16 '24
Sale
0.79
9,304
7,350
14,104
Norry Elliot
Chief Medical Officer
Jan 17 '24
Sale
0.67
18,276
12,300
7,785
Norry Elliot
Chief Medical Officer
Jan 16 '24
Sale
0.79
2,287
1,807
3,363
Lunger John
Chief Patient Supply Officer
Jan 17 '24
Sale
0.67
18,114
12,191
7,785
Lunger John
Chief Patient Supply Officer
Jan 16 '24
Sale
0.79
4,681
3,698
7,023
Bertrand William C JR
Chief Operating Officer
Jan 17 '24
Sale
0.67
18,908
12,725
7,785
Bertrand William C JR
Chief Operating Officer
Jan 16 '24
Sale
0.79
4,681
3,698
7,023
Norry Elliot
Chief Medical Officer
Jan 12 '24
Sale
0.85
7,799
6,661
11,841
Norry Elliot
Chief Medical Officer
Jan 11 '24
Sale
0.84
4,009
3,354
6,104
$21.04
price up icon 1.01%
$69.50
price up icon 1.05%
$355.45
price up icon 1.14%
$42.88
price up icon 2.77%
$184.71
price up icon 0.49%
$115.57
price up icon 0.72%
大文字化:     |  ボリューム (24 時間):